GW Pharmaceuticals (GWPH) announced Monday morning that its Phase 3 clinical trial of Epidiolex, for the treatment of seizures associated with Lennox-Gastaut syndrome, achieved the primary endpoint for both dose levels with high statistical significance.
from RTT - Hot Stocks http://ift.tt/2d3osPa
via IFTTT
No comments:
Post a Comment